NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/18/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization100.28 mln
Float52.44 mln
Earnings Date08/06/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
9.86
Transformational upside
Relative Strength
6
/ 100
Severely lagging
Debt / Equity
0.17
Very low leverage
ROE
-35.03
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Black Diamond Therapeutics is a Cambridge, Massachusetts-based drug development company working to create targeted cancer treatments for patients whose tumors are driven by specific genetic mutations. Its most advanced drug, silevertinib, is currently being tested in two Phase 2 trials for lung cancer and brain tumors, while two additional compounds targeting other cancer-causing genetic changes are progressing through earlier stages of development. Founded in 2014, the company's approach centers on building treatments broad enough to address a wide range of related mutations within a given cancer type, rather than targeting a single genetic variant.
